Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Investment analysts at Desjardins lowered their FY2024 earnings per share estimates for shares of Inovalis Real Estate Investment Trust in a research report issued on Monday, November 11th. Desjardins analyst A. Leon now expects that the company will post earnings per share of $0.01 for the year, down from their previous estimate of $0.06.
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported C($0.29) earnings per share for the quarter. The business had revenue of C$3.52 million during the quarter.
Inovalis Real Estate Investment Trust Price Performance
Inovalis Real Estate Investment Trust Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
See Also
- Five stocks we like better than Inovalis Real Estate Investment Trust
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What is Short Interest? How to Use It
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.
